About the Journal

Download [This article belongs to Volume - 62, Issue - 08 (December 2022)]

Abstract : In the recent decade, the pharmaceutical sector has grown quickly by concentrating on product quality, safety, and efficacy. Scientific technologies like QbD (Quality by Design) and PAT (Process Analytical Technology)have helped pharmaceutical companies boost the amount of new products they generate. There have been ICH recommendations on QbD application in API synthesis and formulation development, which have been discussed in Q8 through Q11. The ICH Q11 guidelines provide examples of the QbD technique used in API synthesis. The USFDA mandates that generic drug manufacturers use the Quality by Design (QbD) strategy when developing new formulations. It is still unclear what regulatory bodies want from analytical development in terms of AQbD (Analytical Quality by Design) and PAT (Process Analytical Technology). API synthesis process and analytical technique development may benefit from combining QbD and AQbD, as outlined in this study. Method optimization and development with DoE, MODR (method operable design region), Control Strategy, AQbD method validation, and continuous method monitoring are some of the most important AQbD tools. These include identifying ATP (Analytical Target Profile), CQA (Critical Quality Attributes), and risk assessment. Quality by Design (QbD) activities may be implemented simultaneously in both synthetic and analytical development, resulting in the best quality product while reducing risks.